Stocks to watch, March 19: Jio Financial Services, GR Infraprojects, Nazara Tech, Vodafone Idea, CG Power, Zydus Life, and more

At 8:02 AM, the GIFT NIFTY futures were trading at 22,953.50, up 23 points, or 0.10%. This implies that the NIFTY50 index will open 58 points higher.

In the overnight trade, US stocks ended lower on Tuesday, ahead of a monetary policy decision from the Federal Reserve, while gauging the potential impact of President Donald Trump's tariff policies.

The Dow Jones Industrial Average fell 260.32 points, or 0.62%, to 41,581.31; the S&P 500 lost 60.46 points, or 1.07%, to 5,614.66; and the Nasdaq Composite lost 304.55 points, or 1.71%, to 17,504.12.

Asian stocks were muted in the morning trade on Wednesday.

Besides, the board has approved the additional fund infusion of up to ₹1,500 crore in Bajaj Auto Credit Limited, a wholly owned subsidiary of the company, either in the form of equity capital/preference capital or subordinated debt, as may be determined in due course, in one or more tranches.

Speaking to reporters on the sidelines of the GCA25 event in Mumbai, Mohanty declined to name the target company but confirmed that negotiations were in their final stages.

For now, Vodafone Idea's 5G services will be offered as an unlimited add-on for plans starting at ₹299, though the duration of this 'introductory offer' has not been specified.

The dividend will be paid on or after April 16, 2025, a regulatory filing said.

The record date for determining the members eligible to receive the interim dividend is March 22, 2025.

The company received an assessment order on March 18, 2025, JK Lakshmi Cement said in a regulatory filing.

"In the said order, the income tax officer has made certain additions to the income of the company as declared in the return of income, resulting in an aggregate demand of ₹4,559.60 lakh," it said.

On the back of the organised gold loan market expected to double in the next five years, the company has drawn up plans to introduce the gold loan business in more branch networks.

The approval by the US Food and Drug Administration (USFDA) is to manufacture Apalutamide tablets of 60 mg strength, Zydus Lifesciences said in a regulatory filing.

The approved Apalutamide tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad, it added.

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer.